ZOETIS (ZTS) Earnings Date & Reports

Key Takeaways

• Zoetis reported Q1 2026 revenue of $2.26 billion, up 3% year-over-year but missing consensus estimates of $2.31 billion.
• Adjusted diluted EPS came in at $1.53, up 9% reported but below expectations of $1.61 by 5%.
• Companion Animal revenue declined 1% to $1.52 billion due to U.S. weakness in dermatology and parasiticides amid price sensitivity and competition.
• Livestock segment grew 15% to $720 million, driven by international strength in cattle, swine, and poultry.
• Company revised FY 2026 guidance lower: revenue $9.68-$9.96 billion (2-5% organic operational growth), adjusted EPS $6.85-$7.00.
• Shares plunged over 20% post-earnings, reflecting investor concerns over U.S. pet care demand and lowered outlook.

Earnings Context and Why It Matters

Zoetis, the world's leading animal health company, released its first quarter 2026 results on May 7, 2026, for the period ended March 31. As a calendar-year fiscal reporter following alignment effective January 1, 2026, this earnings highlighted challenges in the U.S. companion animal market amid pet owner price sensitivity, fewer veterinary visits, and intensified competition in key categories like dermatology and parasiticides. Strong livestock performance and international growth provided some offset, but the misses on estimates and guidance cut underscore broader pressures in premium pet products. For investors, this report signals potential shifts in consumer behavior and competitive dynamics in the $50+ billion global animal health industry, influencing growth trajectories for innovation leaders like Zoetis.

Reported Results

Zoetis posted revenue of $2.26 billion, a 3% increase from Q1 2025 on a reported basis but flat organically (excluding foreign exchange and divestitures), missing Wall Street's $2.31 billion consensus. Net income was $601 million, flat year-over-year, with reported diluted EPS of $1.42, up 6%. Adjusted diluted EPS of $1.53 rose 9% reported (7% organic operational) but fell short of the $1.61 estimate by 5%.

By segment, U.S. revenue dropped 8% to $1.1 billion, with Companion Animal down 11% due to softer demand. International revenue surged 17% (10% organic operational) to $1.1 billion, boosted by livestock. Overall, Companion Animal sales dipped 1% (-4% organic), while Livestock jumped 15% (+12% organic). Adjusted gross margin held steady at 71.8%.

Guidance for full-year 2026 was revised downward to revenue of $9.68-$9.96 billion (2%-5% organic operational growth) and adjusted diluted EPS of $6.85-$7.00, below prior $9.825-$10.025 billion and $7.00-$7.10 ranges, citing U.S. headwinds and fiscal alignment effects.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock analysis workflow.

Market Reaction and Investor Sentiment

Zoetis shares tumbled more than 20% on May 7 following the earnings release, significantly underperforming the broader healthcare sector, as investors reacted to the EPS and revenue misses, U.S. companion animal weakness, and lowered full-year guidance. Pre-market trading saw drops to around $91 before further declines, reflecting disappointment over pet owner price sensitivity and competitive pressures despite livestock gains and a robust pipeline. Sentiment turned cautious, with focus shifting to management's execution plans.

Forward Outlook and Key Factors to Monitor

Zoetis expressed confidence in its diversified portfolio and innovation pipeline, including over 12 potential blockbusters in areas like chronic kidney disease, oncology, and obesity, with expected approvals annually. CEO Kristin Peck highlighted decisive actions to sharpen commercial execution, cost management, and revenue growth amid a tougher U.S. pet care environment.

Investors should watch guidance implications, including 2%-5% organic revenue growth and low- to mid-single-digit adjusted net income expansion. Key near-term catalysts include stabilization of Librela/Solensia sales, Simparica franchise performance, and diagnostics growth (up 10% in Q1). Upcoming product launches like Convenia in Canada and Apoquel in Thailand could provide tailwinds.

Monitor U.S. companion animal demand signals, veterinary visit trends, and competitive dynamics in dermatology/parasiticides. International livestock strength across cattle, swine, poultry, and fish remains a bright spot. Cost discipline, supply continuity, and the planned Neogen genomics acquisition in H2 2026 are additional focal points. Broader industry trends like pet humanization versus economic pressures will shape margin trajectory (adjusted gross ~71%) and R&D investments ($735-$745 million guided).

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations